市場調查報告書

寵物癌症治療的全球市場:成長,趨勢,及預測

Pet Cancer Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 704736
出版日期 內容資訊 英文 118 Pages
商品交期: 2-3個工作天內
價格
Back to Top
寵物癌症治療的全球市場:成長,趨勢,及預測 Pet Cancer Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年09月01日內容資訊: 英文 118 Pages
簡介

本報告提供全球寵物的癌症治療市場的相關調查,市場機會和課題,成長及阻礙因素,各治療、動物、用途、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的假設
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 市場阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各治療
    • 化療
    • 放射線治療
    • 免疫療法
    • 其他
  • 各動物
    • 其他
  • 各用途
    • 淋巴瘤
    • 肥胖細胞癌症
    • 黑色素瘤
    • 乳癌及鱗狀細胞癌
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • Elanco
    • AdvaVet Inc.
    • ELIAS Animal Health
    • Virbac
    • Boehringer Ingelheim GmbH (Merial)
    • Morphogenesis Inc.
    • Radiology Oncology Systems
    • Regeneus Ltd
    • VetDC Inc.
    • IDvet
    • Zoetis

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 64177

Market Overview

The growing prevalence of several types of cancers in cats and dogs, as well as an increase in R&D initiatives regarding cancer management in animals, is contributing to the growth of the market. In addition to the aforementioned factor, growing pet health awareness and rise in R&D initiatives regarding pet cancer management are expected to propel market growth over the forecast period. However, side effects caused by drugs used for the treatment of pet cancers, the reluctance of pet owners to put their pet animals under medication is expected to restrain the pet cancer therapeutics market.

Scope of the Report

As per the scope, Cancer is one of the major causes of death in pets, mainly in dogs that are older than 10 years. However, according to experts, around half of all the prevalent cancers can be cured, if diagnosed early. The success rate of various treatments in preventing and curing neoplasia, and cancer in the pet population, has observed a significant rise over the past few years, as a result of the recent advancements in early recognition, diagnosis, and treatment.

Key Market Trends

Cancers in Dogs are Expected to Lead the Market

Dogs get cancer at about the same rate as humans, while cats get fewer cancers. Some breeds or families of dogs have a higher incidence for developing cancer at an earlier age, but in most cases, it's a disease found in aging animals. According to the Veterinary Cancer Society, cancer is the leading cause of death in 47% of dogs, especially those that are over age 10, and also in 32% of cats. In addition, the growing pet health awareness and a rise in the R&D initiatives regarding pet cancer management are expected to propel the market growth, over the forecast period. For instance, in April 2019 Elanco has signed a development and commercialization agreement with VetDC for Tanovea®-CA1, the first U.S. Food and Drug Administration (FDA) conditionally approved canine lymphoma treatment.

North America Dominates the Pet Cancer Therapeutics Market

North America is expected to retain its significant market share, owing to factors, such as rising pet adoption and increasing per capita animal healthcare expenditure. In addition, the rise in the prevalence of various animal diseases and injuries has been identified as the major factor fueling market growth. Approximately, 90 million dogs are owned in the United States, as per reported by the American Pet Products Association (APPA). In addition, the data published by APPA, in 2019, stated that the total pet healthcare expenditure is estimated to be USD 75.38 billion by the end of the year, while the expenditure in 2018 was USD 72.56 billion. North America also emphasizes on establishing proper skills among veterinary practitioners. Hence, all these factors are driving the growth of the pet cancer therapeutics market in North America.

Competitive Landscape

The market players in the pet cancer therapeutics market are involving in various growth strategies such as collaborations, partnerships, agreements, mergers and acquisitions in order to enhance the market presence. For instance, In April 2019, Elanco Animal Health has signed an agreement to acquire Aratana Therapeutics, pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats and in Jan 2018, Aratana Therapeutics was granted conditional approval for its canine osteosarcoma vaccine, live Listeria vector (AT-014), by the USDA's Center for Veterinary Biologics.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in R&D Initiatives for Cancer Management
    • 4.2.2 High Prevalence of Cancer in Pets
    • 4.2.3 High Prevalence of Cancer in Pets
  • 4.3 Market Restraints
    • 4.3.1 Side Effects Associated with Pet Cancer Therapy
    • 4.3.2 High Cost of Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapy
    • 5.1.1 Chemotherapy
    • 5.1.2 Radiation therapy
    • 5.1.3 Immunotherapy
    • 5.1.4 Other Therapies
  • 5.2 By Animal
    • 5.2.1 Dog
    • 5.2.2 Cat
    • 5.2.3 Other Animals
  • 5.3 By Application
    • 5.3.1 Lymphoma
    • 5.3.2 Mast Cell Cancer
    • 5.3.3 Melanoma
    • 5.3.4 Mammary and Squamous Cell Cancer
    • 5.3.5 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Elanco
    • 6.1.2 AdvaVet Inc.
    • 6.1.3 ELIAS Animal Health
    • 6.1.4 Virbac
    • 6.1.5 Boehringer Ingelheim GmbH (Merial)
    • 6.1.6 Morphogenesis Inc.
    • 6.1.7 Radiology Oncology Systems
    • 6.1.8 Regeneus Ltd
    • 6.1.9 VetDC Inc.
    • 6.1.10 IDvet
    • 6.1.11 Zoetis

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top